Cannabis use among Danish patients with cancer: a cross-sectional survey of sociodemographic traits, quality of life, and patient experiences
- PMID: 34453567
- DOI: 10.1007/s00520-021-06515-z
Cannabis use among Danish patients with cancer: a cross-sectional survey of sociodemographic traits, quality of life, and patient experiences
Abstract
Purpose: Patients with cancer are using cannabis for self-treatment. The reasons, experienced effects, and prevalence of use are unknown in the European general oncological population.
Methods: Adult patients with cancer attending outpatient oncology clinics were invited to participate in a cross-sectional survey. The questionnaire consisted of sociodemographic questions, validated scales on quality of life, neuropathy, anxiety and depression as well as questions regarding use of cannabis.
Results: The overall response rate was 83% (2839 patients) and 13% of patients were using or had used cannabis during their treatment. Rate of use was higher in smokers (19% vs 11%, p adjusted 0.002), in patients in active cancer treatment (14% vs 10%, p adjusted = 0.02), and in patients with depression (19% vs 11%, adjusted p = 0.002). Cannabis use was also correlated with lower quality of life (EORTC C30 SumScore mean diff. = - 7.61, 95% CI = [- 9.69; - 5.53]). In total, 77% of users experienced at least one positive effect of cannabis, 18% experienced no effect, and 5% experienced other effects. At least one side effect was experienced by 33% of users. Management of pain and nausea were the primary reasons for initiating cannabis use (39% for both). Less nausea and better sleep were the most common effects experienced (26% for both). Oils for oral use were the most common route of administration (88%).
Conclusion: Cannabis use among patients with cancer is prevalent and correlated with worse quality of life. Patients report using cannabis for symptom management and many experience relief of their symptoms. However, one third of patients experienced side effects.
Keywords: Alternative medicine; Cannabis; Complimentary medicine; Patient survey; Self-treatment.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Comment in
-
Comment on: Cannabis use among Danish patients with cancer: a cross‑sectional survey of sociodemographic traits, quality of life, and patient experiences.Support Care Cancer. 2022 Nov;30(11):8619-8621. doi: 10.1007/s00520-022-06995-7. Epub 2022 Mar 21. Support Care Cancer. 2022. PMID: 35312856 No abstract available.
References
-
- Martell K, Fairchild A, LeGerrier B et al (2018) Rates of cannabis use in patients with cancer. Curr Oncol 25:219. https://doi.org/10.3747/co.25.3983 - DOI - PubMed - PMC
-
- Pergam SA, Woodfield MC, Lee CM et al (2017) Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer 123:4488–4497. https://doi.org/10.1002/cncr.30879 - DOI - PubMed
-
- Braun IM, Blonquist TM, Campbell EG et al (2019) Medical oncologists’ views on the utility of medical marijuana across the cancer trajectory. J Pain Symptom Manage 57:e1–e4. https://doi.org/10.1016/j.jpainsymman.2019.02.001 - DOI - PubMed
-
- Hershman DL, Lacchetti C, Dworkin RH et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 32:1941–1967. https://doi.org/10.1200/JCO.2013.54.0914 - DOI - PubMed
-
- Roila F, Molassiotis A, Herrstedt J et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27:v119–v133. https://doi.org/10.1093/annonc/mdw270 - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical